Literature DB >> 19011876

[Amyloidoses].

S Ladner-Merz1, U Müller-Ladner.   

Abstract

Amyloidoses make up a group of diseases caused by misfolded proteins. These misfolded proteins are insoluble and are deposited in various tissues and organs, ultimately resulting in severe organ dysfunction. The majority of patients with amlyoidoses suffer from chronic inflammatory, infectious or malignant diseases. Moreover, unexplained nephropathy, cardiomyopathy, neuropathy, enteropathy, arthropathy or macroglossia with or without periorbital bleeding should include an amyloidosis in the differential diagnosis. The latter is facilitated by histological examination of abdominal adipose tissue, the rectum or affected organs. Therapy focuses predominantly on reduction of activity of the underlying disease and specific organ protection. More recent therapeutic strategies include interleukin-1 inhibition, as well as inhibitors of protein misfolding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011876     DOI: 10.1007/s00393-008-0385-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  14 in total

Review 1.  Pathology, diagnosis and pathogenesis of AA amyloidosis.

Authors:  Christoph Röcken; Ann Shakespeare
Journal:  Virchows Arch       Date:  2002-02       Impact factor: 4.064

Review 2.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

Review 3.  [Liver transplantation in familial amyloid polyneuropathy. Case report and review of the literature].

Authors:  M Krüger; K Altland; R P Linke; H Maschek; B Ringe; G Oehler; R Pichlmayr; M P Manns
Journal:  Internist (Berl)       Date:  1997-07       Impact factor: 0.743

4.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

Review 5.  Treatment strategies for amyloid A amyloidosis.

Authors:  T Pettersson; Y T Konttinen; C P J Maury
Journal:  Expert Opin Pharmacother       Date:  2008-08       Impact factor: 3.889

6.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

7.  AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.

Authors:  Ashutosh D Wechalekar; Helen J Lachmann; Hugh J B Goodman; Arthur Bradwell; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

8.  Amyloidosis as a cause of death in patients with rheumatoid arthritis.

Authors:  R Koivuniemi; L Paimela; R Suomalainen; M Leirisalo-Repo
Journal:  Clin Exp Rheumatol       Date:  2008 May-Jun       Impact factor: 4.473

9.  Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.

Authors:  Giovanni Palladini; Paola Russo; Francesca Lavatelli; Mario Nuvolone; Riccardo Albertini; Tiziana Bosoni; Vittorio Perfetti; Laura Obici; Stefano Perlini; Remigio Moratti; Giampaolo Merlini
Journal:  Ann Hematol       Date:  2008-09-09       Impact factor: 3.673

Review 10.  Perspectives in treatment of AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Philip N Hawkins; Julian D Gillmore
Journal:  Br J Haematol       Date:  2007-12-19       Impact factor: 6.998

View more
  2 in total

Review 1.  [Causes and treatment of systemic amyloidosis].

Authors:  N Blank; U Hegenbart; S Schönland
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

Review 2.  Rare Diseases of the Orbit.

Authors:  Ulrich Kisser; Jens Heichel; Alexander Glien
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.